| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Varenicline tartrate (JAN/USAN); Chantix (TN); Champix (TN) | ||||||||
| Product | TYRVAYA (Oyster Point Pharma), CHANTIX (A-S Medication Solutions), CHANTIX (A-S Medication Solutions), CHANTIX (A-S Medication Solutions), CHANTIX (A-S Medication Solutions), CHANTIX (Aphena Pharma Solutions - Tennessee), CHANTIX (Pfizer Labs), CHANTIX (Proficient Rx LP), CHANTIX (Proficient Rx LP), CHANTIX (U.S. Pharmaceuticals) | ||||||||
| Generic | VARENICLINE (American Health Packaging), VARENICLINE (Par Pharmaceutical) | ||||||||
| Formula | C13H13N3. C4H6O6 | ||||||||
| Exact mass | 361.1274 | ||||||||
| Mol weight | 361.3493 | ||||||||
| Structure |  | ||||||||
| Class | Neuropsychiatric agent DG01571 Nicotinic cholinergic receptor partial agonist | ||||||||
| Remark |
| ||||||||
| Efficacy | Smoking cessation adjunct, Selective nicotinic acetylcholine receptor modulator | ||||||||
| Target | CHRNA4/CHRNB2 [HSA:1137 1141] [KO:K04806 K04813] | ||||||||
| Pathway |
| ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] N NERVOUS SYSTEM N07 OTHER NERVOUS SYSTEM DRUGS N07B DRUGS USED IN ADDICTIVE DISORDERS N07BA Drugs used in nicotine dependence N07BA03 Varenicline D06282 Varenicline tartrate (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Anti-Addiction/Substance Abuse Treatment Agents Smoking Cessation Agents Varenicline D06282 Varenicline tartrate (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 7 Agents not mainly for therapeutic purpose 79 Other agents not mainly for therapeutic purpose 799 Miscellaneous 7990 Miscellaneous D06282 Varenicline tartrate (JAN/USAN) Drug groups [BR:br08330] Neuropsychiatric agent DG01571 Nicotinic cholinergic receptor partial agonist DG00995 Varenicline D06282 Varenicline tartrate Target-based classification of drugs [BR:br08310] Ion channels Ligand-gated ion channels Acetylcholine (nicotinic) CHRNA4/CHRNB2 D06282 Varenicline tartrate (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D06282 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D06282 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D06282 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D06282 Drug groups [BR:br08330] Neuropsychiatric agent DG01571 Nicotinic cholinergic receptor partial agonist DG00995 Varenicline | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 26 1 C8y C 5.3200 -5.3900 2 C1y C 4.2000 -4.4800 3 C1x C 2.8700 -4.8300 4 N1x N 2.2400 -6.0900 5 C8y C 5.3200 -6.7900 6 C1x C 2.8700 -7.3500 7 C1y C 4.2000 -7.6300 8 C8x C 6.5324 -7.4900 9 C8y C 7.7449 -6.7900 10 C8y C 7.7449 -5.3900 11 C8x C 6.5324 -4.6900 12 N5x N 8.9573 -7.4900 13 C8x C 10.1697 -6.7900 14 C8x C 10.1697 -5.3900 15 N5x N 8.9573 -4.6900 16 C1x C 3.5547 -6.0585 17 O6a O 12.2731 -5.6706 18 C6a C 13.4856 -6.3706 19 C1c C 14.6981 -5.6706 20 C1c C 15.9105 -6.3706 21 C6a C 17.1231 -5.6706 22 O6a O 18.3355 -6.3706 23 O6a O 13.4856 -7.7705 24 O1a O 14.6981 -4.2705 25 O1a O 15.9105 -7.7706 26 O6a O 17.1231 -4.2708 BOND 28 1 3 4 1 2 1 5 1 3 4 6 1 4 2 3 1 5 5 7 1 6 1 2 1 7 6 7 1 8 5 8 2 9 8 9 1 10 9 10 2 11 10 11 1 12 1 11 2 13 9 12 1 14 12 13 2 15 13 14 1 16 14 15 2 17 10 15 1 18 2 16 1 19 7 16 1 20 17 18 1 21 18 19 1 22 19 20 1 23 20 21 1 24 21 22 1 25 18 23 2 26 19 24 1 #Down 27 20 25 1 #Down 28 21 26 2 |